Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.53 USD | +3.01% | +13.54% | +24.74% |
Sales 2024 * | 87.83M 120M | Sales 2025 * | 258M 352M | Capitalization | 3.35B 4.59B |
---|---|---|---|---|---|
Net income 2024 * | -329M -450M | Net income 2025 * | -204M -279M | EV / Sales 2024 * | 36 x |
Net cash position 2024 * | 194M 265M | Net cash position 2025 * | 451M 617M | EV / Sales 2025 * | 11.3 x |
P/E ratio 2024 * |
-9.74
x | P/E ratio 2025 * |
-12.9
x | Employees | 305 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.94% |
Latest transcript on SpringWorks Therapeutics, Inc.
1 day | +3.01% | ||
1 week | +13.54% | ||
Current month | -7.50% | ||
1 month | -9.12% | ||
3 months | +7.41% | ||
6 months | +110.69% | ||
Current year | +24.74% |
Managers | Title | Age | Since |
---|---|---|---|
Saqib Islam
CEO | Chief Executive Officer | 54 | 17-07-31 |
Daniel Lynch
CHM | Chairman | 65 | 15-12-31 |
Frank Perier
DFI | Director of Finance/CFO | 64 | 19-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Fuhrman
BRD | Director/Board Member | 67 | 19-07-31 |
Freda Lewis-Hall
BRD | Director/Board Member | 69 | 17-07-31 |
Carlos Alban
BRD | Director/Board Member | 61 | 22-07-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.11% | 0 M€ | 0.00% | - | |
0.10% | 0 M€ | 0.00% | - | |
0.08% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 45.53 | +3.01% | 898,993 |
24-04-25 | 44.2 | +1.89% | 999,789 |
24-04-24 | 43.38 | -1.41% | 504,700 |
24-04-23 | 44 | +2.59% | 867,347 |
24-04-22 | 42.89 | +6.96% | 867,694 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.74% | 3.35B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- SWTX Stock